We found that there may be little or no difference in overall survival (OS) between weekly paclitaxel and three‐weekly paclitaxel, but the evidence is very uncertain. https://t.co/EsXQkY1rZ3
RT @CochraneJapan: 再発上皮性卵巣がんの女性患者に対する単剤化学療法としてのタキサンの投与計画 https://t.co/OPaa9O5g2w
RT @CochraneJapan: 再発上皮性卵巣がんの女性患者に対する単剤化学療法としてのタキサンの投与計画 https://t.co/OPaa9O5g2w
再発上皮性卵巣がんの女性患者に対する単剤化学療法としてのタキサンの投与計画 https://t.co/OPaa9O5g2w
RT @Cochrane_GNOCG: Will fewer people experience neutropenia when given weekly rather than three‐weekly paclitaxel? https://t.co/sBgwsJHks…
RT @Cochrane_GNOCG: Will fewer people experience neutropenia when given weekly rather than three‐weekly paclitaxel? https://t.co/sBgwsJHks…
Will fewer people experience neutropenia when given weekly rather than three‐weekly paclitaxel? https://t.co/sBgwsJHksT @BrittaStordal #ovariancancer
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer https://t.co/Hn5WpqVnAd